812P - Post hoc responder analysis of health‐related quality of life (HRQL) in patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials
| Autor: | Thiery Vuillemin, A., Fizazi, K., Sartor, O., Oudard, S., Bury, D., Guillonneau, S., Ozatilgan, A., Eisenberger, M., de Bono, J.S. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|